A new study from the Veterans Health Administration, which has not yet been peer-reviewed, has found that a 5-day course of Pfizer’s Paxlovid can reduce the risk of severe illness and hospitalization from COVID-19. Researchers are also reporting that the antiviral medication may prevent those who take it from developing long COVID, a condition that experts are working to better understand.